Data on Potential Biomarker for Qualigen Therapeutics’ Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
08 mars 2023 08h05 HE
|
Qualigen Therapeutics, Inc.
S100P Gene Expression May Be Marker of Anti-Tumor Activity in Pancreatic Cancer In Vivo Models CARLSBAD, Calif., March 08, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the...
Qualigen Therapeutics Chief Executive Officer Michael Poirier Provides Letter to Stockholders
01 févr. 2023 09h05 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer
10 janv. 2023 09h00 HE
|
Qualigen Therapeutics, Inc.
CARLSBAD, Calif., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for...
Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
16 août 2022 07h30 HE
|
Qualigen Therapeutics, Inc.
Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic...
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
07 juin 2022 09h04 HE
|
Qualigen Therapeutics, Inc.
A Potential Treatment for Pancreatic Cancer in Addition to Other Tumors of High Unmet Clinical Need CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq:...
Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex
02 juin 2022 09h00 HE
|
Qualigen Therapeutics, Inc.
Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market ...
Qualigen Therapeutics’ Pan-RAS Inhibitor Featured in Two Abstracts at American Society for Clinical Oncology (ASCO) 2022 Annual Meeting
26 mai 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Abstracts Highlight In Vitro and In Vivo Activity of Qualigen’s Pan-RAS inhibitor in (1) Pancreatic Cancer, and (2) Malignant Peripheral Nerve Sheath Tumors CARLSBAD, Calif., May 26, 2022 (GLOBE...
Qualigen Therapeutics Presents Three Posters of QN-302 at American Association of Cancer Research Conference
12 avr. 2022 10h15 HE
|
Qualigen Therapeutics, Inc.
Data Highlights In Vivo Research and the Potential Mechanism of Action in Pancreatic and Prostate Cancers CARLSBAD, Calif., April 12, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc....
Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research Conference
22 mars 2022 09h15 HE
|
Qualigen Therapeutics, Inc.
Abstracts Review Positive In vivo Data and the Potential Mechanism of Action for QN-302 in Pancreatic and Prostate Cancers CARLSBAD, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Qualigen...